

The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

Rafal M. Kaminski · Michael A. Rogawski ·
Henrik Klitgaard

Published online: 27 March 2014

© The American Society for Experimental NeuroTherapeutics, Inc. 2014

Abstract A major goal of contemporary epilepsy research is the identification of therapies to prevent the development of recurrent seizures in individuals at risk, including those with brain injuries, infections, or neoplasms; status epilepticus; cortical dysplasias; or genetic epilepsy susceptibility. In this review we consider the evidence largely from preclinical models for the antiepileptogenic activity of a diverse range of potential therapies, including some marketed antiseizure drugs, as well as agents that act by immune and inflammatory mechanisms; reduction of oxidative stress; activation of the mammalian target of rapamycin or peroxisome proliferator-activated receptors γ pathways; effects on factors related to thrombolysis, hematopoiesis, and angiogenesis; inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase; brain-derived neurotrophic factor signaling; and blockade of $\alpha 2$ adrenergic and cannabinoid receptors. Antiepileptogenesis refers to a therapy of which the beneficial action is to reduce seizure frequency or severity outlasting the treatment period. To date, clinical trials have failed to demonstrate that antiseizure drugs have such disease-modifying activity. However, studies in animal models with levetiracetam and ethosuximide are encouraging, and clinical trials with these agents are warranted. Other promising strategies are inhibition of interleukin 1β signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin

by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the $\alpha 2$ adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity. These approaches could lead to a new paradigm in epilepsy drug therapy where treatment for a limited period prevents the occurrence of spontaneous seizures, thus avoiding lifelong commitment to symptomatic treatment.

Keywords Antiepileptogenic drug · Kindling model · Pilocarpine model · Anti-inflammatory · Sphingosine 1-phosphate receptor modulator · mTOR inhibitor

Introduction

Antiepileptic drugs, now commonly referred to as antiseizure drugs (ASDs), provide symptomatic benefit by preventing the occurrence of seizures in an individual at risk. ASD discovery and development has generated nearly 40 clinically effective agents since the introduction of potassium bromide by Sir Charles Locock in 1857 [1]. A major reason for this impressive productivity has been the availability of predictive animal screening models, particularly the maximal electroshock and pentylenetetrazol tests [2]. These models have led to the discovery of most presently used ASDs [3]. The current armamentarium of available ASDs effectively prevent seizures in many patients, but none has been shown to delay the onset or prevent the occurrence of epilepsy, and all have troubling side effects. Similarly, epilepsy treatment devices such as the vagal nerve stimulator and the responsive neurostimulator have not been demonstrated to confer disease modification. This leaves resective surgery as the only existing cure for epilepsy, and emphasizes a major unmet need for disease-modifying therapies that truly affect the underlying epilepsy [4]. Disease-modifying therapies may prevent or

Electronic supplementary material The online version of this article (doi:10.1007/s13311-014-0266-1) contains supplementary material, which is available to authorized users.

R. M. Kaminski · H. Klitgaard (✉)
Neuroscience TA, UCB Pharma, Braine-l'Alleud, Belgium
e-mail: henrik.klitgaard@ucb.com

M. A. Rogawski
Department of Neurology, University of California, Davis School of
Medicine, Sacramento, CA, USA

delay the onset of spontaneous recurrent seizures in an individual at risk; they may reverse already established epilepsy; or they may prevent or ameliorate comorbidities, such as cognitive deficits that accompany some forms of epilepsy [5]. The key difference distinguishing disease-modifying therapies from symptomatic therapies is that the benefit conferred by disease-modifying therapies persists after drug treatment is withdrawn. For the purposes of this article, we mainly focus on treatments that prevent or delay the onset of epilepsy; such a treatment is referred to as “antiepileptogenic”. Antiepileptogenesis can also refer to conditions in which epilepsy develops despite treatment, but it is less severe, that is the seizure frequency is reduced, seizures are of shorter duration, or the seizure type is milder. Furthermore, antiepileptogenic treatment may also result in amelioration of comorbidities associated with epilepsy [6]. Evaluation of antiepileptogenic approaches often includes an assessment of their ability to protect against neural injury, although such injury is not a necessary part of epileptogenesis; in this review we may mention such results if they seem relevant.

It is believed that seizures occur when the excitability in certain brain circuits exceeds the restraints imposed by inhibitory mechanisms [7]. Although clinically used ASDs were all identified on the basis of animal models that are not biased with respect to mechanism, ASD mechanisms—to the extent they are understood—generally fall into two categories: negative modulation of excitatory mechanisms or positive modulation of inhibitory mechanisms [4, 8]. Agents that act in either of these ways effectively prevent seizures for many patients, but there is no reason to believe that targeting these same physiological mechanisms would lead to a beneficial modification in the underlying disease process [9]. In recent years, there has been an intense effort to understand the pathophysiological mechanisms underlying epileptogenesis, which has revealed new pathways and potential targets for future drug therapies intended to prevent or alter the course of the epileptogenic process [4]. Among the hypothetical mechanisms postulated to contribute to epileptogenesis are inflammation, neurodegeneration, blood–brain barrier (BBB) disruption, and acquired and genetically encoded changes in the functional activity or expression of ion channels or transporters. Attempts are being made to discover and develop novel agents that address these mechanisms and to repurpose drugs from other therapeutic areas with activities that could be beneficial when applied to epilepsy. The nature of potential antiepileptogenic agents may differ markedly from traditional small-molecule ASDs, and could include peptides, antibodies, nucleic acids, or even cellular or gene therapies. Challenges will be encountered in delivering these agents to the appropriate brain regions and in avoiding systemic side effects. Specialized carriers or delivery mechanisms may be required to address these issues (see, e.g., Rogawski [10]).

The first part of this article reviews the preclinical and clinical data obtained with current ASDs that have demonstrated antiepileptogenic properties in animal models. These include the older ASDs valproate and ethosuximide, and the newer agents topiramate and levetiracetam. The second part of the article considers novel mechanisms, targets, and agents. There is discussion of potential antiepileptogenic agents that modulate immune and inflammatory mechanisms; reduce oxidative stress; activate certain secondary messenger systems; influence thrombolysis, hematopoiesis, and angiogenesis targets; inhibit 3-methylglutaryl-coenzyme A (HMG-CoA) reductase; brain-derived neurotrophic factor (BDNF) signaling; block α_2 adrenergic and cannabinoid receptors; and influence Cl^- homeostasis. When subjected to scrutiny, it is apparent that the support for certain of these mechanisms is sufficiently limited that it will be difficult to muster enthusiasm for attempts at clinical validation. In other cases, the base of evidence is more compelling: additional preclinical studies are of high priority, and clinical studies may soon be undertaken.

ASDs with Potential Antiepileptogenic Properties

Even though all currently used ASDs were discovered as a result of their ability to protect against seizures in rodent screening models, it has been of interest to assess whether these agents could potentially have antiepileptogenic properties. This has been facilitated by the availability of various animal models of epilepsy, including kindling, brain injury, and syndrome-specific models, as well as several rodent strains that exhibit reduced seizure threshold or spontaneous seizures [11, 12]. Although none of these models has been clinically validated as a tool for identifying agents that have antiepileptogenic activity in human epilepsy, they do permit proof-of-concept data to be generated to support clinical studies. There is some evidence that valproate [13] and levetiracetam [14, 15] may cause a delay in kindling acquisition that persists beyond the period of drug exposure, suggesting an antiepileptogenic action. In addition, long-term treatment with ethosuximide and levetiracetam has recently demonstrated a compelling ability to reduce the development of seizures in genetic animal models of absence epilepsy [16, 17]. The reduction in seizures persists after the treatment is withdrawn, suggesting a true antiepileptogenic effect. Post-traumatic epilepsy is considered the most feasible clinical situation for evaluating antiepileptogenic drug treatments. To date, phenytoin, phenobarbital, the combination of phenytoin and phenobarbital, carbamazepine, valproate, and magnesium have been rigorously studied in clinical trials for their ability to prevent the development of post-traumatic epilepsy [18]. None was found to have an antiepileptogenic effect. Comparable clinical trials have not been conducted with newer ASDs, although several, including topiramate and levetiracetam, exhibit

activity in certain animal antiepileptogenesis models [19], and, to date, human trials with levetiracetam suggest that additional study of this agent is warranted [20, 21].

Valproate

Valproate is one of the major older ASDs, possessing broad spectrum activity against diverse seizure types. While the precise way in which valproate protects against seizures is still obscure, the drug has a variety of actions, including effects on Na^+ and T-type Ca^{2+} channels, and also on γ -aminobutyric acid (GABA) metabolism [8]. In addition, valproate is well recognized as an inhibitor of histone deacetylases [22] and may counteract aberrant neurogenesis [23], which might confer antiepileptogenic properties.

Studies have been conducted in the amygdala kindling model comparing the potential antiepileptogenic properties of valproate to carbamazepine and phenobarbital [13]. Valproate treatment prior to each kindling stimulation prevented the development of kindled behavioral seizures, which was interpreted as an antiepileptogenic action. However, valproate—at the doses used—also markedly reduced the duration of the afterdischarge (epileptiform discharge recorded by the stimulating electrode). Therefore, an alternative explanation of the result is that the drug treatment prevents the electrical stimulus from triggering the local seizure discharge that leads to epileptogenesis, but that it does not have a specific effect on the downstream events leading to epileptogenesis. The results with valproate contrast with NMDA, which can inhibit kindling development without attenuating the afterdischarge [24, 25]. Interestingly, in the study by Silver et al. [13], when kindling stimulation was continued in the absence of drug pretreatment, the afterdischarge duration was attenuated on the first stimulation without drug pretreatment when the drug was believed to have been completely cleared. In addition, in animals that had received high doses of valproate prior to kindling stimulations, kindling acquisition seemed delayed after drug treatment was stopped. Thus, this study raises the possibility that valproate could have a limited true antiepileptogenic action, apart from its ability to suppress the seizure discharge.

Further studies involving post-status epilepticus (SE) epileptogenesis models have found conflicting results with valproate. A first study in immature rats reported that valproate treatment following SE counteracted ensuing deficits in visuospatial learning, prevented histologic lesions, and there was an absence of spontaneous seizures [26]. However, the assessment of seizures was conducted at a time in which the animals were not completely drug free, raising questions as to whether the seizure suppression truly reflected an antiepileptogenic effect. In contrast, other studies have found that valproate treatment following SE studies in adult rats did not affect the later development of spontaneous seizures in

drug-deprived animals, despite prevention of hippocampal damage [27, 28].

The lack of compelling evidence for an antiepileptogenic action of valproate in animals models in combination with a clinical study that failed to demonstrate a beneficial effect of valproate treatment on the development of epilepsy following traumatic brain injury (TBI) [18] reduces enthusiasm for valproate as a disease-modifying therapy. Also, valproate did not display any positive impact on cognitive function or psychopathology in the clinical study. However, issues related to choice of dose, timing of treatment initiation, and duration, as well as comorbid conditions in patients with TBI, such as drug and alcohol abuse and memory problems, render successful execution of clinical trials difficult in this population, so the interpretation of such studies is problematic [29]. Therefore, there is still uncertainty regarding the potential for valproate as an antiepileptogenic therapy.

Ethosuximide

Ethosuximide was introduced nearly 5 decades ago and continues to constitute a first-line treatment for the symptomatic treatment of absence seizures. Its primary mechanism relates to inhibition of T-type Ca^{2+} channels [30]. Recent experimental data obtained in genetic animal models now suggest that ethosuximide also may provide an antiepileptogenic therapy for absence epilepsy.

The first evidence that ethosuximide has such activity came from a study in WAG/Rij rats that exhibit spike-and-wave discharges (SWDs) during the course of their development [16]. Treatment was initiated 3 weeks after birth with ethosuximide in the drinking water and continued until 5 months of age. The exposure covered a period from before the onset of SWDs to a time in development when they are well established. The number, but not duration, of the SWDs was found to be markedly suppressed during 3 months of sequential recordings performed after termination of treatment, revealing an antiepileptogenic potential of ethosuximide. This observation has been reproduced in subsequent studies [17, 31] and extended to another genetic animal model for human absence epilepsy—the GAERS rat [32]. Furthermore, ethosuximide also seems to prevent comorbid anxiety [32] and depression [31, 33] in the genetic absence epilepsy models, based upon observations in the open field and the forced swim test, respectively.

The mechanism underlying the remarkable effects of ethosuximide remains to be determined. Knowing that ethosuximide is a relatively selective inhibitor of T-type Ca^{2+} channels it is intriguing to speculate that the effect on T-type Ca^{2+} channels could be responsible. Indeed, T-type Ca^{2+} channels seem to play a critical role in the epileptogenic process in the mouse pilocarpine SE model [34]. In this model, increased T-type Ca^{2+} current and intrinsic burst firing

in hippocampal CA1 pyramidal neurons was associated with later spontaneous seizure expression. In contrast, these hallmarks of epileptogenesis were virtually absent following pilocarpine-induced SE in mice lacking T-type Ca^{2+} channels, and these knockout mice had a reduced propensity for spontaneous seizures. These studies raise the possibility that chronic block of T-type Ca^{2+} channels by ethosuximide could prevent epileptogenesis, as it does in the T-type Ca^{2+} channel knockouts. It has also been observed that antiepileptogenic treatment with ethosuximide in the WAG/Rij rat prevented activity-dependent changes in the expression of Nav 1.1, Nav 1.6, and HCN1 ion channels, which may reduce excitability and contributed to the reduced emergence of seizures [16]. Furthermore, antiepileptogenic treatment with ethosuximide in the GAERS rat model was also shown to modulate epigenetic mechanisms by increasing the expression of DNA methyltransferase enzyme messenger RNA in cortex [32].

The promising preclinical data obtained with ethosuximide suggest that clinical trials would be worthwhile. Treatment duration seems of importance, as one study in WAG/Rij rats showed that treatment for 4 months was required, whereas a shorter treatment duration of 2 months was ineffective [31]. All studies with ethosuximide have so far been conducted with treatment initiated prior to onset of SWD, and have not examined whether chronic treatment initiated after the onset of SWD would also provide antiepileptogenic effects. The ability to deliver treatment after the onset of symptoms would markedly enlarge the therapeutic potential. In addition, given the results in the pilocarpine SE model linking T-type Ca^{2+} channels to epileptogenesis, it would be of interest to examine the utility of ethosuximide in other epilepsies.

Topiramate

Topiramate is a newer, structurally novel ASD with multiple pharmacological actions that could contribute to its ability to protect against seizures [8]. These include modulatory effects on Na^+ and Ca^{2+} channels, GABA_A receptors, and ionotropic glutamate receptors. This combination of actions has encouraged studies of the antiepileptogenic potential of topiramate.

An early study showed that topiramate could delay amygdala kindling in rats [35]. However, the protocol involved drug administration at the time of kindling stimulation and the afterdischarge was reduced, raising similar questions as in the case of valproate. More recent studies demonstrated an age-dependent ability to retard kindling acquisition in a rat rapid kindling model, with increasing efficacy as the age of the animals increased from 2 to 5 weeks [36, 37]. As with the prior study in adult rats, the translatability of the findings is uncertain.

An initial preliminary study in the rat pilocarpine model of SE found topiramate to be both neuroprotective and antiepileptogenic [38]. Treatment with topiramate after SE markedly reduced the number of animals that subsequently developed spontaneous seizures. These intriguing findings encouraged additional studies, some of which were confirmatory, including a study in mature rats in the pilocarpine SE model [39] and in immature rats in the lithium–pilocarpine model [40]. However, several other studies in mature rats failed to confirm these results [41–43]. The inconsistency regarding the antiepileptogenic effects of topiramate in SE models contrasts with the more consistent finding that treatment of immature and mature rats with topiramate after lithium–pilocarpine- and pilocarpine-induced SE mitigates the ensuing cognitive impairment [43–45] and has neuroprotective properties [39, 41, 43, 45, 46].

The consistent ability of topiramate to attenuate cognitive impairment and neuronal injury in rat SE models coincides with reports showing that topiramate treatment promotes neurological recovery in rats following TBI induced by lateral fluid percussion or by the weight-drop technique [47, 48]. Interestingly, this effect may, at least partially, reflect an ability of topiramate to reduce glutamate release after TBI [49]. A pilot clinical trial to investigate the prevention of epilepsy in TBI was initiated, but is not currently ongoing [50].

Levetiracetam

Levetiracetam is another newer ASD which, like topiramate, possesses a novel chemical structure and has diverse pharmacological actions [51]. For example, the drug reduces high voltage-activated Ca^{2+} currents, inhibits intracellular Ca^{2+} release through the IP3 and ryanodine receptors associated with the endoplasmic reticulum, reverses the inhibitory effects of zinc on both GABA_A - and glycine receptor-mediated currents, and inhibits AMPA. However, the most likely target of relevance to the antiseizure actions of levetiracetam is synaptic vesicle protein 2A (SV2A), a ubiquitous presynaptic protein. SV2A-deficient mice show a marked reduction in the anticonvulsant activity of levetiracetam, confirming the role of SV2A in the seizure protection conferred by the drug [52]. Interestingly, SV2A expression has also been observed to be suppressed during the epileptogenic process in rat SE models and in hippocampal tissue from epilepsy patients. In addition, SV2A-deficient mice exhibit a proepileptic phenotype and accelerated epileptogenesis [53]. These various observations support a role for SV2A in the development of epilepsy, and raise the possibility that levetiracetam could have antiepileptogenic properties aside from its antiseizure activity.

In support of this possibility, numerous studies have demonstrated that levetiracetam counteracts the process of kindling when administered immediately before kindling stimulation during the acquisition of kindling [14, 15, 54–57]. As for valproate (see above), levetiracetam was tested using an

experimental design consisting of a first phase in which drug treatment is administered before each kindling stimulation, and a second phase in which daily kindling stimulation is continued, but without drug pretreatment [14, 15]. In a first study, it was demonstrated that levetiracetam causes a dose-dependent inhibition of kindling development in rats, as assessed by behavioral seizure stage and also inhibits the increase in afterdischarge duration that occurs during kindling [14]. At a higher dose, but not at lower doses, the diminished afterdischarge duration persisted despite continued stimulation in the absence of drug pretreatment, indicating a persistent effect of the drug. However, the persistent kindling resistance did not extend to the behavioral seizure stage, which did increase with continued stimulation. These findings were reproduced in another study by a different group that showed levetiracetam to cause a persistent lack of increase in afterdischarge duration after cessation of treatment [15].

Studies in genetic animal models of epilepsy have consistently shown antiepileptogenic properties of levetiracetam, when administered before the developmental expression of seizure activity. This was first demonstrated in a strain of spontaneously epileptic rats from Kyoto University in which early long-term treatment with a therapeutically relevant dose of levetiracetam inhibited the developmental expression of tonic convulsions and SWDs associated with absence seizures [58]. Later studies in the WAG/Rij rats confirmed that early long-term treatment with a therapeutically relevant dose of levetiracetam inhibits the developmental expression of SWDs [17, 33].

In contrast to the results obtained in kindling and genetic models, studies in SE models have provided conflicting results with respect to levetiracetam's antiepileptogenic properties. Studies in rats with SE induced by pilocarpine and electrical stimulation of the amygdala did not find chronic treatment with levetiracetam after SE to inhibit the later development of spontaneous seizures [28, 59]. In contrast, other studies in rats using paired perforant path stimulation, kainic acid, and pilocarpine for SE induction showed a significant ability of chronic treatment with levetiracetam after SE to reduce the number [60] and duration of subsequent spontaneous motor seizures [61]. In addition, the development of hippocampal hyperexcitability, as manifested by increased population spike amplitude in the dentate gyrus and reduced paired-pulse inhibition in the CA1 area, was inhibited [62]. With the exception of one study [59], levetiracetam has also exhibited neuroprotective properties in SE studies [28, 63] and an ability to suppress seizure-induced neurogenesis [62], whereas cognitive impairment induced by SE was not prevented [59, 63].

Experience from a limited number of human studies supports the antiepileptogenic potential of levetiracetam. An uncontrolled, retrospective analysis of patients undergoing

craniotomy and treated postoperatively with either levetiracetam or phenytoin showed that fewer patients who received levetiracetam (26 %) developed epilepsy after 1 year than those treated with phenytoin (36 %), although the difference did not reach statistical significance [20]. A recent open-label, nonrandomized study in 126 adults and children assessing the safety, tolerability, and pharmacokinetics of levetiracetam treatment in TBI patients for 1 month, initiated within 8 h of the injury, also showed a nonsignificant trend toward fewer patients on levetiracetam treatment (11 %) developing epilepsy after 2 years than those who were untreated (20 %) [21]. An additional pilot study in 40 children aged 6–17 years in which half were treated with levetiracetam within 8 h of injury showed an overall low incidence of posttraumatic epilepsy [64]. Only one patient developed epilepsy, and this patient was in the treatment group. This study is inconclusive as to the effect of levetiracetam. Moreover, a benefit on seizure occurrence after TBI was not observed in a small randomized, single-blinded, comparative trial of levetiracetam versus phenytoin in patients with severe TBI [65].

Interestingly, a recent retrospective analysis of seizure outcome implications of ASD use in patients who underwent temporal lobectomy demonstrated perioperative use of levetiracetam to predict a more favorable outcome [66]. While all ASDs were equally effective soon after surgery, at 5 years, patients taking levetiracetam exhibited a substantial “seizure freedom advantage” over other drugs, including carbamazepine, lamotrigine, oxcarbazepine, phenytoin, and topiramate. The authors speculated that this might reflect an antiepileptogenic action of levetiracetam under the assumption that the late recurrence of epilepsy reflects a new epileptogenic process following removal of the original epileptic focus. Overall, the available preclinical and clinical data indicate that continued evaluation of the antiepileptogenic potential of levetiracetam is worthwhile. More generally, it will be of interest to assess the role of pharmacological modulation of SV2A in antiepileptogenesis. In this context it is noteworthy that the selective, high-affinity SV2A ligand brivaracetam shows more pronounced antiepileptogenic effects than levetiracetam in the kindling model [57].

Novel Antiepileptogenic Targets and Agents

Although certain antiseizure drugs do have potential antiepileptogenic properties there is no reason to believe that an antiepileptogenic agent must protect against seizures or even that seizure suppression is a beneficial property for an antiepileptogenic therapeutic. Currently, there is an intense research effort focused on understanding the scientific basis of epileptogenesis. As a spin-off of this effort, a wide range of new molecular targets for antiepileptogenesis are being identified (see, e.g., Kobow et al. [67]). In many cases, these

targets are entirely different from those that have been defined through studies of the mechanism of action of antiepileptic drugs. To date, no novel antiepileptogenic drug has been identified as a result of screening against a unique antiepileptogenic target. Rather, studies have been conducted using previously known agents with central nervous system activity. In most cases, agents have been selected for study based on hypotheses regarding antiepileptogenic mechanisms. The strategy is to “repurpose” therapeutic agents designed for different purposes, for example to modulate immune function, reduce oxidative stress, or stimulate red cell production. The fact that many of these agents are already approved for use in other disease indications will facilitate evaluation of the novel strategies in human clinical studies. In the remainder of this article, we consider the evidence for the antiepileptogenic activity of various agents that are not traditional ASDs and that act on diverse putative antiepileptogenic mechanisms.

Immune and Inflammatory Mechanisms

Rapidly mounting evidence indicates a potential role of inflammation in the pathophysiology of epilepsy and epileptogenesis [68, 69]. A large number of inflammatory mechanisms have been implicated, but only relatively few have been experimentally investigated using pharmacological tools in animal epilepsy models. Marketed drugs and compounds in clinical development that possess specific anti-inflammatory actions are of particular interest in probing the therapeutic relevance of these mechanisms as they can be quickly translated into clinical development as epilepsy treatments.

Interleukin 1 β Pathway

The interleukin 1 β (IL1 β) pathway is one of the best characterized inflammatory pathways in epilepsy. Seminal work performed by Dr. Annamaria Vezzani and her collaborators has provided compelling evidence for a pathophysiological role of IL1 β in epilepsy [68]. In animal models, the levels of IL1 β in the brain are elevated during epileptogenesis and also (to a lesser degree) during chronic epilepsy. Importantly, studies with brain tissue obtained at surgery for temporal lobe epilepsy (TLE) or focal cortical dysplasia have revealed that similar changes occur in human epilepsy. Furthermore, injection of IL1 β into the brain leads to seizure exacerbation in rodents, while IL1 β knockout mice are resistant to seizures. These observations have created a strong rationale for testing therapeutic modalities that inhibit IL1 β synthesis in models of chronic epilepsy. For example, VX-765 is an orally active IL-converting enzyme/caspase-1 inhibitor that blocks IL1 β secretion and produces a strong anti-inflammatory effect [70]. Subchronic treatment (4 days) with VX-765 before acute kainate injection reduces the duration and number of seizures

during SE [71]. Moreover, treatment with VX-765 after epilepsy is established in the postkainate SE model, resulting in a reduction in the duration and number of spontaneous recurrent seizures [72]. A recent study extends this concept [73]. In these recent experiments, IL1 β signaling was blocked by systemic administration of the recombinant IL1 receptor antagonist (anakinra) and VX-765. These compounds were administered either 60 mins after pilocarpine-induced SE or 180 mins after unrestrained electrically induced SE, and the treatment continued for 7 days. The drug combination significantly decreased IL1 β expression and exerted a neuroprotective effect, although the onset of epilepsy and the frequency and duration of seizures were not significantly modified. While these particular studies did not indicate an antiepileptogenic action, VX-765 may have antiepileptogenic properties as it is able to delay kindling development [74]. The antiseizure mechanism of anti-inflammatory drugs that inhibit IL1 β signaling seem quite different from most of the conventional ASDs acting on voltage-gated ion channels or inhibitory/excitatory mechanisms. However, IL1 β may facilitate or exacerbate seizures via indirect modulation of NMDA receptors [75], and it will be of interest to further explore the disease-modifying potential of such treatments. Indeed, a recent trial with VX-765 in patients with treatment-resistant partial epilepsy did not meet the predefined endpoint, but a post-hoc analysis suggested that the treatment might produce a reduction in seizure frequency that is slow to develop, but which persists for at least 2 weeks after the drug is discontinued [76]. These encouraging, but preliminary, results represent the first evidence in humans that targeting immune mechanisms may have a role in epilepsy treatment.

Leukocyte Adhesion

Leukocytes and leukocyte adhesion mechanisms may play a role in seizure generation and in the pathology of epilepsy [77]. Experimental data from a mouse model of TLE indicate that seizures cause increased expression of vascular cell adhesion molecules, and enhance leukocyte rolling and arrest in brain vessels [78]. These effects could be mediated by specific leukocyte integrins, such as $\alpha 4\beta 1$ integrin [very late antigen-4 (VLA-4)]. Remarkably, inhibition of leukocyte-vascular interactions with blocking antibodies markedly reduced seizures in this animal model, but, more importantly, treatment with blocking antibodies after SE prevented the development of epilepsy [78]. Interestingly, there is evidence that leukocyte infiltration into the brain is more abundant in individuals with epilepsy than in controls [78]. However, more recently, Zattoni et al. [79] have shown that in the kainate model leukocyte infiltration may actually be neuroprotective and could inhibit epileptogenesis. Thus, the role of immune cell trafficking during epileptogenesis is not fully elucidated, and may be dependent on experimental model or epilepsy

syndrome. For example, the presence of T cells in human epilepsy tissue is not an unequivocal finding as it has only been established in focal cortical dysplasia type 2b, while a minor infiltration is observed in focal cortical dysplasia type 1, and virtually no infiltration is observed in TLE [80, 81]. Nevertheless, these observations suggest that inhibition of leukocyte migration into the brain could be a promising therapeutic strategy in epilepsy. This is particularly attractive as the VLA-4 blocking antibody natalizumab is already approved for the treatment of multiple sclerosis [82]. Small molecules blocking VLA-4 are also at different stages of clinical development [83] and could become useful tools to probe these mechanisms further in animal models of epilepsy.

Cyclooxygenase-2

Cyclooxygenases are enzymes responsible for the formation of prostanoids, complex fatty acids that have diverse roles in inflammation. Selective inhibitors of cyclooxygenase-2 (COX-2) were developed to reduce the risk of peptic ulceration that occurs with nonselective cyclooxygenase inhibitors. There are several reports from experimental epilepsy models suggesting that COX-2 inhibitors may have potential disease-modifying properties; however, the results have not been consistent [84]. Jung et al. [85] reported that celecoxib has antiepileptic and neuroprotective effects in the lithium–pilocarpine model in rats. In this study, treatment with celecoxib was started 24 h after SE and continued during the seizure monitoring period. Celecoxib-treated animals showed a significantly reduced incidence of spontaneous recurrent behavioral seizures as detected in video recordings in the period 28–42 days after SE. In addition, the duration of seizures that occurred in the celecoxib-treated animals was reduced compared with those in vehicle-treated rats, and there was a neuroprotective effect in various hippocampal regions. In a later study, a different COX-2 inhibitor (SC58236) was investigated in the self-sustaining SE model [86]. Treatment with the COX-2 inhibitor was begun a few hours after the onset of SE and continued for 7 days. The animals were monitored by video-electroencephalography recording for 35 days. An additional experimental group was treated with SC58236 for 5 days after the development of spontaneous recurrent seizures. In contrast to the study of Jung et al. [85], treatment with SC58236 did not result in any significant effect on seizure incidence, duration, latency to the first spontaneous seizure, or seizure severity. In addition, no significant neuroprotection was observed in the SC58236-treated animals. Interestingly, the same group later reported that treatment with SC58236 before SE induction led to increased lethality within the first 2 weeks of SE, and 14-day treatment in chronic epileptic rats led to an increase in seizures in some animals [87]. In a third study, Polascheck et al. [88] used parecoxib, a prodrug of the potent and selective COX-2 inhibitor

valdecoxib, in the rat pilocarpine model of TLE. In this study, the treatment was started 90 mins after SE and continued for 18 days. Despite thorough video-electroencephalography monitoring for 8 weeks, there was no evidence that parecoxib treatment led to a reduction in the incidence, frequency, or duration of spontaneous seizures or in the behavioral and cognitive alterations associated with epilepsy. The authors did find a mild effect of parecoxib treatment on seizure severity, and it appeared to reduce neuronal injury in the hippocampus.

Unfortunately, clinical use of selective COX-2 inhibitors has been associated with significantly increased risk of cardiovascular diseases [89, 90]; therefore, an alternative strategy selectively targeting of individual prostaglandin receptors has been proposed. Indeed, recent data indicate that small molecule inhibitors of prostaglandin E2 receptor subtype EP2 are neuroprotective when administered after SE [91, 92]. Even though these compounds do not display clear-cut antiseizure or antiepileptogenic properties, at least when early seizures after SE are concerned, EP2 receptor antagonism could be an adjunctive therapeutic strategy for the pathological sequelae of SE or brain injury [91, 92].

Together, these studies suggest that despite strong induction of COX-2 during epileptic seizures pharmacological inhibition of this enzyme alone or selective inhibition of prostaglandin receptors may not be sufficient to provide a robust disease-modifying effect. However, COX-2 or prostaglandin E2 receptor inhibitors might provide benefit when used in conjunction with other anti-inflammatory treatments, such as IL1 β inhibitors [93].

Sphingosine 1-Phosphate Receptors

Sphingosine 1-phosphate receptors belong to a large family of G protein-coupled receptors that are expressed by many cell types, including immune, glial, and neural cells. Fingolimod (FTY720), a sphingosine analog that acts as a sphingosine 1-phosphate receptor modulator, is an approved oral treatment for relapsing forms of multiple sclerosis. Fingolimod inhibits lymphocyte egress, selectively retaining lymphocytes within the lymph nodes, but, in addition, it acts on a number of neuronal and non-neuronal cells to exert neuroprotective and anti-inflammatory effects in the brain [94]. Although fingolimod has not been widely studied in epilepsy models, a recent report by Gao et al. [95] indicates that it may also have therapeutic potential in epilepsy. In this study, fingolimod was administered to rats in the lithium–pilocarpine model for 14 days beginning 24 h after SE. Interestingly, fingolimod produced a clear-cut neuroprotective effect, inhibiting pathological mossy fiber sprouting, decreasing activation of microglia and restoring abnormal expression of IL1 β and tumor necrosis factor- α in the hippocampus. Furthermore, the incidence, duration, frequency, and severity of spontaneous

recurrent seizures was significantly decreased in fingolimod-treated animals [95]. These results are encouraging and suggest that further study is warranted.

Oxidative Stress Mechanisms

Oxidative stress, a biochemical state in which harmful reactive oxygen species are generated, has been hypothesized to occur in epilepsy and to be a cause of treatment refractoriness [96, 97]. Several antioxidant strategies have been proposed as a treatment approach. Here, we consider resveratrol, a stilbenoid found in the skin of red grapes and other fruits that demonstrates strong antioxidant and neuroprotective properties [98], and dimethyl fumarate, which exerts cytoprotective effects by induction of an antioxidant response [99].

Resveratrol

A plethora of largely preclinical studies has found broad therapeutic potential of resveratrol in the treatment of diverse conditions, including metabolic syndromes, cancer, and cardiovascular diseases. Some, but not all, recent experimental studies also suggest that resveratrol may have utility in epilepsy [100]. Wu et al. [101] examined the effects of resveratrol treatment on the occurrence of spontaneous seizures following SE induced by intrahippocampal kainate injection in rats. The incidence and rate of spontaneous seizures was markedly reduced in the resveratrol treatment group. The effect on seizures was associated with neuroprotection in the hippocampus, as well as a reduction in mossy fiber sprouting [101]. These promising results were not fully confirmed in a more recent study of younger kainate-treated rats [102], so that, at present, the potential of resveratrol for disease modification in epilepsy is uncertain.

Nrf2 Pathway

Nuclear erythroid-2-related factor 2 (Nrf2) is a redox-sensitive, basic leucine zipper transcription factor. Under physiological conditions, Nrf2 is sequestered in the cytoplasm, tethered to the regulatory protein Keap1. Oxidative stress or other disturbances in cell homeostasis lead to nuclear translocation of Nrf2, where it binds to the antioxidant response element in promoters of target genes. Overall, Nrf2 coordinates the expression of numerous genes encoding detoxification, antioxidant, and anti-inflammatory mediators, and calcium homeostasis and signaling proteins resulting in an orchestrated protective response. Nrf2 has been described as the “master regulator” of the antioxidant response, and it represents a molecular target with broad therapeutic potential [103]. Indeed, Nrf2 exerts a protective role in a number of neurodegenerative disease models [104]. Interestingly, Nrf2 has also been identified to be at the center of a network of over

250 coexpressed genes that were specifically altered in the hippocampi of animals with kainate-induced seizures [105]. Furthermore, Nrf2-deficient animals are more vulnerable to kainate-induced seizures [106]. Recently, Mazzuferi et al. [107] confirmed that Nrf2 is activated in hippocampal tissue obtained from patients and mice with TLE. They also reported that overexpression of Nrf2 by viral gene transfer in mice with TLE led to seizure reduction, as well as neuroprotective and anti-inflammatory effects. Together, these recent results provide a strong rationale for the investigation of small molecule activators the Nrf2 pathway to treat epilepsy. Several natural products and synthetic molecules that activate the Nrf2 pathway are under development or already approved for clinical use [108]. For example, dimethyl fumarate (BG-12) has recently been licensed for the treatment of relapsing–remitting multiple sclerosis [109]. It remains to be determined whether this compound, or other Nrf2 activators, will indeed provide therapeutic efficacy in epilepsy.

Signaling Pathways

The Mammalian Target of Rapamycin Pathway

The mammalian target of rapamycin (mTOR) is a well-conserved serine/threonine kinase of the phosphatidylinositol kinase-related kinase family [110]. In brain, it plays a role in neurite growth, synaptic plasticity and cell survival by regulating metabolism and protein synthesis [110, 111]. The mTOR signaling pathway is critical to tuberous sclerosis (TS), a genetic multisystem disorder characterized by hamartomas in several organs, including the brain. Patients with TS usually have seizures. The disease occurs as a result of mutations in the TSC1 and TSC2 tumor suppressor genes, which act as negative regulators of the mTOR complex. A mutation in TSC1 or TSC2 results in hyperactivation of mTOR and its downstream genes, causing tumor formation [112, 113]. Recent studies have indicated that mTOR plays a role in the epileptogenic process in TS inasmuch as early treatment with the mTOR inhibitor rapamycin can prevent the development of epilepsy in mice with conditional inactivation of the *Tsc1* gene [114]. A retrospective clinical study confirmed the potential utility of rapamycin for the treatment of seizures in children with TSC; whether this action is disease-modifying remains to be determined [115]. Interestingly, mTOR dysregulation has been demonstrated in a variety of other types of epilepsy, including epilepsies associated with brain injury, SE, genetic mutations, brain tumors, and focal cortical dysplasias [116]. Indeed, mTOR inhibitors may have antiseizure and antiepileptogenic actions in various types of acquired epilepsy [114, 117, 118]. The efficacy of rapamycin in TLE models is inconsistent, and may be dependent on study design, model or species choice [119–121]. Consequently,

mTOR inhibition may not be a universal antiepileptogenic strategy.

Peroxisome Proliferator-Activated Receptors

The peroxisome proliferator-activated receptors (PPARs) constitute a group of three nuclear receptor isoforms: PPAR γ , PPAR α , and PPAR δ . They operate as ligand-regulated transcription factors, which heterodimerize with retinoid X receptor and upon agonist binding interact with various cofactors to initiate gene transcription. Fatty acids are the natural ligands for PPARs, which thereby serve as lipid sensors and regulators of lipid metabolism. Consequently, synthetic PPAR ligands have been developed for the treatment of dyslipidemias and diabetes. However, emerging research indicates broader potential of these ligands as therapies for atherosclerosis, inflammation, cancer, demyelination, and several neurological diseases [122].

Many PPAR γ agonists have been tested in various models of epilepsy and it has generally been found that these agents protect against seizures. For example, pioglitazone delayed the development of seizures in genetically epileptic EL mice, which was associated with overall reduction in several neuroinflammation biomarkers [123]. Fenofibrate displayed anti-convulsant effects in the lithium–pilocarpine SE model and against pentylentetrazol-induced seizures [124]. Another PPAR γ agonist, rosiglitazone, consistently displayed significant neuroprotective effects and attenuated inflammatory responses after induction of SE [125–127]. Importantly, intracerebroventricular rosiglitazone administered prior to the administration of lithium–pilocarpine also decreased the number of spontaneous recurrent seizures in the chronic phase beginning 2 weeks after SE, although it did not affect the severity of SE in the acute phase; some of its protective effects were indirectly mediated by TrkB signaling [128]. PPAR γ agonists seem to have promise as anticonvulsant agents and there is a suggestion that they might be disease-modifying. Given the availability of diverse PPAR agonists that are approved for use in other clinical indications, further investigation of this class of agents is warranted in epilepsy.

Thrombolysis, Hematopoiesis, and Angiogenesis

Tissue-Type Plasminogen Activator

Tissue-type plasminogen activator (tPA) is a serine protease that catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for thrombolysis (clot breakdown) [129]. Ordinarily, tPA is expressed at low levels in the brain, but its synthesis is increased by seizures [130]. The exact role of tPA is not well characterized in the brain, and its primary substrates could be different from that in blood. Interestingly, both tPA and plasminogen knockout mice are more resistant to

kainic acid induced seizures than their wild-type littermates [131, 132]. tPA knockout mice display reduced seizure-dependent mossy fiber sprouting, but plasminogen knockout mice do not share this phenotype [133], suggesting that plasmin may not be the primary substrate for tPA within the central nervous system. Mutation of the neuroserpin gene, which is a serine proteinase inhibitor of tPA, has been associated with progressive myoclonic epilepsy raising the possibility that epileptogenesis occurs when tPA activity in brain is unrestrained by neuroserpin [134]. Consistent with this conclusion is the observation that administration of tPA promotes the propagation of kainate-induced seizures, an effect that is plasminogen-independent, but which can be blocked by the administration of neuroserpin [135]. Collectively, the data raise the possibility that strategies to reduce the activity of brain tPA or increase the activity of neuroserpin could be antiepileptogenic. At present, however, centrally active agents with the appropriate activities are not yet available.

Erythropoietin

Erythropoietin (EPO), a glycoprotein hormone that controls erythropoiesis in the bone marrow, has other actions that have been widely recognized, including effects in the central nervous system [136]. In particular, there is evidence that exogenous EPO administration can protect against seizures [137, 138]. Moreover, EPO receptors are expressed by hippocampal neurons, and their abundance is increased following lithium–pilocarpine SE [139, 140]. This may occur because SE increases transcript levels of hypoxia-inducible factor-1 α , the regulatory subunit of hypoxia-inducible factor-1, which regulates the gene for EPO and vascular endothelial growth factor (VEGF; see below). In a recent study of rats subjected to lithium–pilocarpine SE, EPO administration started immediately after SE cessation and continued for 7 days led to prevention of BBB leakage, neuronal death, and microglia activation, and inhibited the ectopic granule cell generation that occurs with epileptogenesis [140]. More importantly, EPO treatment reduced the risk for the development of spontaneous recurrent seizures and led to a reduction in the seizure duration. An obvious concern with the use of EPO is that there could be a dangerous increase in red cell production. However, the dosing regimen used in this study does not elevate the hematocrit beyond safe levels. A separate study found similar neuroprotective effects of EPO in a rat model of SE [141]. Interestingly, Eid et al. [142] demonstrated an increased density of EPO receptors in sclerotic hippocampi resected from patients with treatment-resistant TLE. It will be of interest to determine the mechanism whereby EPO protects against epileptogenesis, and clinical evaluation may be warranted.

VEGF

Profound cerebrovascular changes are observed in patients with focal epilepsies and in rodent models, which appear to be an important factor for the development and maintenance of the disease pathology [143]. In rodent models of TLE, BBB impairment occurs early after SE and is typically followed by a progressive increase in vascularization. However, in humans and rodents, ongoing angiogenesis and BBB disruption are still evident in the epileptic focus during the chronic phase of the disease, probably as a result of ongoing recurrent seizures [144]. VEGF is a key signal promoting angiogenesis, but it also alters BBB permeability and enhances monocyte infiltration into brain parenchyma. These and other actions of VEGF directly or indirectly affect neuronal excitability, brain plasticity, and the biology of several neurological diseases, including epilepsy [145]. Numerous reports confirm that there is a rapid increase in VEGF expression and signaling shortly after SE induction, and this enhanced VEGF activity persists in the chronic phase of focal epilepsies [145–148]. If VEGF is involved in the maintenance of the epileptic state, anti-VEGF therapies such as bevacizumab and ranibizumab that are marketed for several cancer indications and for ophthalmic diseases could be beneficial in therapy of epilepsy or epileptogenesis. It is possible that therapeutic antibodies such as bevacizumab are able to penetrate the BBB, although whether and under what conditions this occurs is uncertain [149]. Unfortunately, VEGF plays an important neuroprotective role so that approaches aiming at diminution of VEGF signaling could be problematic [145, 150]. VEGF-R2, a receptor tyrosine kinase, mediates most of the cellular responses to VEGF, including its neuroprotective actions. Targeting VEGF-R2 could, theoretically, be an alternative antiepileptogenic strategy [151]. However, in line with the role of VEGF in neuroprotection, blocking VEGF-R2 was found to increase hippocampal neuronal loss in a model of TBI [152]. Moreover, VEGF-R2 overexpression in mice exerted an antiseizure effect, but failed to affect kindling epileptogenesis [153]. At present, there is insufficient information to conclude that VEGF or its receptors are appropriate targets for an antiepileptogenic therapy.

Other Molecular Targets

Inhibition of HMG-CoA Reductase

Statins are a class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver [154]. In addition, this class of compound exerts a plethora of other actions, including modulation of inflammatory responses and improvement of endothelial functions [155]. Therefore, statins may have broad therapeutic utility, including for the treatment of neurological diseases. Interestingly, there has been a flurry of

reports providing evidence that statins could be useful in the treatment of epilepsy. For example, treatment with atorvastatin and simvastatin produced clear-cut neuroprotective and anti-inflammatory effects in the kainate model of TLE [156, 157], while lovastatin inhibited aberrant mossy fiber sprouting in the pilocarpine model [158]. In contrast, atorvastatin had no significant effect on brain inflammation and neuronal death in the self-sustaining SE model [159]. Moreover, in none of these cases did treatment with statins affect the frequency of spontaneous recurrent seizures. Interestingly, however, treatment with lovastatin corrected excess hippocampal protein synthesis and prevented epileptogenesis in *Fmr1* mice, a model of fragile X syndrome in which the *Fmr1* gene is deleted [160]. It is noteworthy that the genetic defect in these mice differs from that in the human disorder, where there is a CGG trinucleotide repeat expansion. These animals exhibit audiogenic seizures, but not other seizure types, and they do not exhibit a reduced seizure threshold to chemoconvulsants; the significance of the audiogenic seizures that occur in these animals for human fragile X syndrome is uncertain.

In a recent epidemiological study, a large patient cohort with cardiovascular diseases, treated with statins, was compared with patients not on these medications. Patients taking a statin were less likely to be hospitalized for epilepsy, suggesting that statins might play a role in the prevention or treatment of epilepsy in populations at high risk of seizures [161]. Although the results are intriguing, this observational study requires confirmation with prospective trials.

Neurotrophic Factors

Emerging evidence suggests that activation of BDNF receptor TrkB promotes epileptogenesis caused by SE. Indeed, animal models of TLE are associated with a strong increase in BDNF expression and enhanced activation of TrkB, while infusion of BDNF and transgenic overexpression of BDNF or TrkB increase seizure susceptibility or severity. Consequently, conditional knockout of *TrkB* completely abolishes epileptogenesis in the kindling model [162]. Combined augmentation of fibroblast growth factor-2 (FGF-2) and BDNF increased neurogenesis, reduced neuronal loss, and, most importantly, reduced the occurrence of spontaneous seizures in a model of TLE [163]. Interestingly, antiepileptogenic effects of FGF-2 and BDNF might involve inhibition of neuroinflammatory mechanisms [164]. These exciting observations have been confirmed recently and extended to another post-SE model of epileptogenesis in which transient inhibition of TrkB achieved by a chemical–genetic approach prevented the onset of recurrent seizures, ameliorated anxiety-like behaviors, and limited loss of hippocampal neurons [165]. These recent findings have more firmly established FGF-2 and TrkB signaling as an attractive target for developing preventive treatments for human epilepsies.

$\alpha 2$ Adrenergic Receptor Blockade

Adrenergic receptors are a family of G protein-coupled receptors that serve as the targets of the neurotransmitter norepinephrine. Several decades of research have demonstrated that pharmacological activation or blockade of the various adrenergic receptor types can influence seizure susceptibility. Specifically, stimulation of $\alpha 2$ adrenergic receptors is generally anticonvulsant, while blockade of these receptors is proconvulsant [166]. Therefore, the observation of Pitkänen et al. [167] that inhibition of $\alpha 2$ adrenergic receptors may have disease-modifying and neuroprotective effects in a model of TLE is intriguing. In this study, chronic treatment with atipamezole, a selective $\alpha 2$ adrenergic receptor antagonist, was started 1 week after the induction of SE by electrical stimulation of the amygdala. Although there were no differences in the proportion of animals that developed epilepsy, the atipamezole-treated rats displayed lower seizure frequency, and the seizure frequency did not increase over time as in the control animals. Furthermore, atipamezole-treated animals had less damage in the hilar region of the hippocampus and less pronounced mossy fiber sprouting, although this did not correlate with the severity of the epilepsy. Inasmuch as atipamezole, like other $\alpha 2$ adrenergic receptor blockers, has proconvulsant activity [168], this study clearly rebuts the conventional view that assumes antiseizure treatments will lead to antiepileptogenesis. In fact, just the opposite might be true. At present, it is not known whether the effect of atipamezole seen in this study will extend to other epilepsy models, whether antiepileptogenesis is a general property of proconvulsant agents (repeated treatment with certain proconvulsant agents leads to kindling, so caution is warranted), and whether it would be feasible to use a proconvulsant agent clinically. Nevertheless, this study has been influential in changing thinking about the appropriate strategy to pursue in the search for disease-modifying agents in epilepsy [6].

Cannabinoid Receptors

Cannabinoid receptor antagonists provide another example of agents that enhance brain excitability, but which may paradoxically confer antiepileptogenesis. Many studies have demonstrated that cannabinoid agonists are acutely anticonvulsant, whereas cannabinoid antagonists, including the selective CB1 antagonist SR141716A (rimonabant), are acutely proconvulsant [169]. Surprisingly, however, SR141716A treatment prevents the development of increased seizure susceptibility when administered during or shortly after a brain insult in models of prolonged febrile seizures [170] or TBI [171]. The observation that the cannabinoid system can regulate epileptogenesis indicates that caution is warranted when contemplating the use of agents that interact with cannabinoid signaling in epilepsy therapy.

$Na^+K^+2Cl^-$ Cotransporter

In immature neurons in the developing brain, the balance between $Na^+K^+2Cl^-$ cotransporter (NKCC1) and K^+Cl^- cotransporter activity is such that the Cl^- equilibrium potential is more positive than in adult neurons so that the neurotransmitter GABA causes depolarization. If GABA is depolarizing, seizures may occur, which could lead to epileptogenesis [172, 173]. Depolarizing GABA may also be relevant to epileptogenesis in the adult brain. Various epileptogenic brain insults downregulate K^+Cl^- cotransporter and upregulate NKCC1 causing a recapitulation of the state of hyperexcitability in the immature brain. Bumetanide, an inhibitor of NKCC1, prevents the outward flow of Cl^- , opposing the shift in Cl^- equilibrium potential and the depolarizing action of GABA, which leads to an anticonvulsant action [174, 175]. By treating rats chronically with bumetanide in the pilocarpine-induced SE model of TLE, Brandt et al. [176] examined the hypothesis that depolarizing GABA is a factor in epileptogenesis. No significant effect on development of spontaneous seizures was obtained. This negative result was later confirmed in the presence of a metabolic inhibitor that increases bumetanide brain exposure [177]. A small observational clinical case series indicates that bumetanide might confer seizure protection in patients with treatment-resistant TLE [172]. Thus, agents that block NKCC1 might provide symptomatic benefit under some circumstances, but there is no evidence that they would be antiepileptogenic [173].

Conclusion

Evidence from preclinical studies indicates that certain ASDs, including levetiracetam, ethosuximide, and possibly valproate, may produce effects on seizure susceptibility that outlast the treatment period, suggesting that these agents might have disease-modifying activity in epilepsy. To date, no ASD has been demonstrated to have antiepileptogenic activity in a rigorous clinical trial. However, the most promising drugs, notably levetiracetam and ethosuximide, have not been adequately studied. Whether they can provide clinically useful disease-modifying effects is uncertain, but some attempts are being made to find out [21, 64]. Although the emphasis to date in antiepileptogenesis clinical trials has almost exclusively been on antiseizure drugs, it is apparent that an antiepileptogenic agent need not have antiseizure activity, and the evidence from studies of atipamezole and SR141716A indicates that even drugs with proconvulsant activity can have antiepileptogenic properties.

At present, there are many theories of epileptogenesis, but none are firmly established. However, the diverse theories of epileptogenesis currently under investigation suggest many potential treatment approaches. There are a remarkable

number of treatments that were developed for other disease indications and are now in clinical use, which, the theories suggest, could be antiepileptogenic. These treatments could be repurposed for epilepsy therapy. Clinical studies can be expected with many of these agents.

It is worth noting that epilepsy encompasses many distinct conditions and it seems unlikely that a single agent will be universally antiepileptogenic in all epilepsies. More likely, disease-modifying treatments will be specific to the epilepsy type. An important consideration is the timing of the treatment. Early treatment before epilepsy is established is most likely to be successful. For many epilepsy types, this will require predictive biomarkers, which are not available at present [178]. Also, new clinical trial designs are urgently required [5]. The recent clinical trial of VX-765, which was originally developed as a treatment for autoimmune conditions and represents the first nonconventional therapy to be studied in humans, lends credence to the repurposing strategy. However, the study was structured as a conventional epilepsy drug trial and failed to meet its predefined endpoint. It was only when the investigators considered the novel biological actions of VX-765 as an antiinflammatory agent and reanalyzed the data to recognize the possibility that benefit might develop slowly, but persist beyond the course of treatment, that it was possible to discern a suggestion of efficacy. Clearly, the design of clinical trials of potential antiepileptogenic agents will need to be founded on a deep understanding of the underlying biological mechanisms, as well as comprehensive knowledge of the pharmacology of the therapeutic agent. Despite the not inconsequential hurdles, the base of relevant scientific information is expanding rapidly and there is cause for cautious optimism. It is not difficult to imagine that in the not too distant future antiepileptogenic therapies will emerge, ushering in a new era in which physicians administer drug treatment for a limited period to prevent the occurrence of epilepsy instead of committing patients to an often lifelong course of one or more symptomatic treatments.

Acknowledgments This work was supported by grants from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NS079292) to M.A.R. H.K. and R.M.K. are employees of UCB. M.A.R. declares no competing interests.

Required Author Forms Disclosure forms provided by the authors are available with the online version of this article.

References

- Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. *Epilepsia* 2011;52:657–678.
- Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. *Epilepsia* 2013;54(Suppl. 4):24–34.
- Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. *Lancet Neurol* 2007;6:793–804.
- Löscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. *Nat Rev Drug Discov* 2013;12:757–776.
- Schmidt D, Friedman D, Dichter MA. Anti-epileptogenic clinical trial designs in epilepsy: Issues and options. *Neurotherapeutics* 2014. doi: 10.1007/s13311-013-0252-z.
- Pitkänen A. Therapeutic approaches to epileptogenesis—hope on the horizon. *Epilepsia* 2010;51(Suppl. 3):2–17.
- Nadler JV. Plasticity of glutamate synaptic mechanisms. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (eds) *Jasper's basic mechanisms of the epilepsies*. 4th ed. National Center for Biotechnology Information, Bethesda, MD, 2012, available at: <http://www.ncbi.nlm.nih.gov/books/NBK98204>. Accessed March 16, 2014.
- Porter RJ, Dhir A, Macdonald RL, et al. Mechanisms of action of antiseizure drugs. *Handb Clin Neurol* 2012;108:663–681.
- Margineanu DG, Klitgaard H. Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery. *Expert Opin Drug Discov* 2009;4:23–32.
- Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. *Neurotherapeutics* 2009;6:344–351.
- Klitgaard H, Matagne A, Schachter S, et al. Animal and translational models of the epilepsies. In: Animal and translational models of behavioral disorders. McArthur RA, Borsini F (eds) XXX. Elsevier, New York, 2008, pp. 311–335.
- White HS, Löscher W. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. *Neurotherapeutics* 2014. doi: 10.1007/s13311-013-0250-1
- Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. *Ann Neurol* 1991;29:356–363.
- Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. *J Pharmacol Exp Ther* 1998;284:474–479.
- Stratton SC, Large CH, Cox B, et al. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. *Epilepsy Res* 2003;53:95–106.
- Blumenfeld H, Klein JP, Schridde U, et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. *Epilepsia* 2008;49:400–409.
- Russo E, Citraro R, Scicchitano F, et al. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. *Epilepsia* 2010;51:1560–1569.
- Temkin NR. Preventing and treating posttraumatic seizures: the human experience. *Epilepsia* 2009;50(Suppl. 2):10–13.
- Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: Experimental approaches and translational research. *Pharmacol Rev* 2010;62:668–700.
- Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. *Neurology* 2008;71:665–669.
- Klein P, Herr D, Pearl PL, et al. Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. *Arch Neurol* 2012;69:1290–1295.
- Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J Biol Chem* 2001;276:36734–36741.
- Jessberger S, Nakashima K, Clemenson GD Jr, et al. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. *J Neurosci* 2007;27:5967–5975.

24. Holmes KH, Bilkey DK, Laverty R, et al. The N-methyl-D-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures. *Brain Res* 1990;506:227–235.
25. Dürmüller N, Craggs M, Meldrum BS. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. *Epilepsy Res* 1994;17:167–174.
26. Bolanos AR, Sarkisian M, Yang Y, et al. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. *Neurology* 1998;51:41–48.
27. Brandt C, Gastens AM, Sun M, et al. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. *Neuropharmacology* 2006;51:789–804.
28. Klitgaard HV, Matagne AC, Vanneste-Goemaere J, et al. Effects of prolonged administration of levetiracetam on pilocarpine-induced epileptogenesis in rat. *Epilepsia* 2001;42(Suppl. 7):114.
29. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. *Epileptic Disord* 2012;14:105–113.
30. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nature Med* 2004;10:685–692.
31. van Luijtelaar G, Mishra AM, Edelbroek P, et al. Antiepileptogenesis: Electrophysiology, diffusion tensor imaging and behavior in a genetic absence model. *Neurobiol Dis* 2013;60:126–138.
32. Dezsi G, Ozturk E, Stanic D, et al. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. *Epilepsia* 2013;54:635–643.
33. Russo E, Citraro R, Scicchitano F, et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. *Epilepsia* 2011;52:1341–1350.
34. Becker AJ, Pitsch J, Sochivko D, et al. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. *J Neuroscience* 2008;28:13341–13353.
35. Amano K, Hamada K, Yagi K, et al. Antiepileptic effects of topiramate on amygdaloid kindling in rats. *Epilepsy Res* 1998;31:123–128.
36. Mazarati A, Shin D, Auvin S, et al. Age-dependent effects of topiramate on the acquisition and the retention of rapid kindling. *Epilepsia* 2007;48:765–773.
37. Sankar R, Auvin S, Kwon YS, et al. Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling. *Epilepsia* 2010;51(Suppl. 3):39–42.
38. DeLorenzo RJ, Morris A, Blair RE, et al. Topiramate is both neuroprotective and antiepileptogenic in the pilocarpine model of status epilepticus. *Epilepsia* 2002;43(Suppl. 7):15.
39. Kudin AP, Debska-Vielhaber G, Vielhaber S, et al. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. *Epilepsia* 2004;45:1478–1487.
40. Suchomelova L, Baldwin RA, Kubova H, et al. Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects. *Pediatr Res* 2006;59:237–243.
41. Rigoulot MA, Koning E, Ferrandon A, et al. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. *J Pharmacol Exp Ther* 2004;308:787–795.
42. François J, Koning E, Ferrandon A, et al. The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. *Epilepsy Res* 2006;72:147–163.
43. Shatskikh T, Zhao Q, Zhou JL, et al. Effect of topiramate on cognitive function and single units from hippocampal place cells following status epilepticus. *Epilepsy Behav* 2009;14:40–47.
44. Cha BH, Silveira DC, Liu X, et al. Effect of topiramate following recurrent and prolonged seizures during early development. *Epilepsy Res* 2002;51:217–232.
45. Frisch C, Kudin AP, Elger CE, et al. Amelioration of water maze performance deficits by topiramate applied during pilocarpine-induced status epilepticus is negatively dose-dependent. *Epilepsy Res* 2007;73:173–180.
46. Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. *Brain Res* 1999;837:263–269.
47. Hoover RC, Motta M, Davis J, et al. Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. *J Neurotrauma* 2004;21:501–512.
48. Kouzounias K, Kimiskidis VK, Siozos T, et al. Topiramate promotes neurological recovery in a new model of traumatic brain injury in rats. *Neuroscience* 2011;183:171–177.
49. Alves OL, Doyle AJ, Clausen T, et al. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. *Ann NY Acad Sci* 2003;993:25–34.
50. Dichter MA. Posttraumatic epilepsy: the challenge of translating discoveries in the laboratory to pathways to a cure. *Epilepsia* 2009;50(Suppl. 2):41–45.
51. Klitgaard H, Verdu P. Levetiracetam – the first SV2A ligand for the treatment of epilepsy. *Expert Opin Drug Discov* 2008;2:1537–1545.
52. Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (eds) *Jasper's basic mechanisms of the epilepsies*. 4th ed. National Center for Biotechnology Information, Bethesda, MD: National Center, 2012, available at <http://www.ncbi.nlm.nih.gov/books/NBK98183>. Accessed March 16, 2014.
53. Kaminski RM, Gillard M, Leclercq K, et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. *Epilepsia* 2009;50:1729–1740.
54. Gu J, Lynch BA, Anderson D, et al. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. *Eur J Neurosci* 2004;19:334–345.
55. Husum H, Bolwig TG, Sánchez C, et al. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. *Epilepsy Behav* 2004;5:204–215.
56. Vinogradova LV, van Rijn CM. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. *Epilepsia* 2008;49:1160–1168.
57. Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. *Br J Pharmacol* 2008;154:1662–1671.
58. Yan HD, Ji-qun C, Ishihara K, et al. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). *Epilepsia* 2005;46:1170–1177.
59. Brandt C, Glien M, Gastens AM, et al. Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. *Neuropharmacology* 2007;53:207–221.
60. Mazarati AM, Baldwin RA, Klitgaard H, et al. Treatment with levetiracetam during the latent period after experimental status epilepticus reduces chronic spontaneous recurrent seizures. *Epilepsia* 2003;44(Suppl. 9):223.
61. Sugaya Y, Maru E, Kudo K, et al. Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. *Brain Res* 2010;1352:187–199.

62. Margineanu DG, Matagne A, Kaminski RM, et al. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. *Brain Res Bull* 2008;77:282–285.
63. Zhou JL, Zhao Q, Holmes GL. Effect of levetiracetam on visual-spatial memory following status epilepticus. *Epilepsy Res* 2007;73:65–74.
64. Pearl PL, McCarter R, McGavin CL, et al. Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy. *Epilepsia* 2013;54:135–137.
65. Szaflarski JP, Snagha KS, Lindsell CJ, et al. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. *Neurocrit Care* 2010;12:165–172.
66. Jehi LE, Irwin AI, Kayyali H, et al. Levetiracetam may favorably affect seizure outcome after temporal lobectomy. *Epilepsia* 2012;53:979–986.
67. Kobow K, Auvin S, Jensen F, et al. Finding a better drug for epilepsy: antiepileptogenesis targets. *Epilepsia* 2012;53:1868–1876.
68. Vezzani A, Balosso S, Ravizza T. Inflammation and epilepsy. *Handb Clin Neurol* 2012;107:163–175.
69. Devinsky O, Vezzani A, Najjar S, et al. Glia and epilepsy: excitability and inflammation. *Trends Neurosci* 2013;36:174–184.
70. Stack JH, Beaumont K, Larsen PD, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. *J Immunol* 2005;175:2630–2634.
71. Ravizza T, Lucas SM, Balosso S, et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. *Epilepsia* 2006;47:1160–1168.
72. Maroso M, Balosso S, Ravizza T, et al. Interleukin-1 β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. *Neurotherapeutics* 2011;8:304–315.
73. Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1 β /IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. *Neurobiol Dis* 2013;59:183–193.
74. Ravizza T, Noé F, Zardoni D, et al. Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1 β production. *Neurobiol Dis* 2008;31:327–333.
75. Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1 β enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. *J Neurosci* 2003;23:8692–8700.
76. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). *Epilepsy Res* 2013;103:2–30.
77. Fabene PF, Laudanna C, Constantin G. Leukocyte trafficking mechanisms in epilepsy. *Mol Immunol* 2013;55:100–104.
78. Fabene PF, Navarro Mora G, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. *Nat Med* 2008;14:1377–1383.
79. Zattoni M, Mura ML, Deprez F, et al. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. *J Neurosci* 2011;31:4037–4050.
80. Ravizza T, Gagliardi B, Noé F, et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. *Neurobiol Dis* 2008;29:142–160.
81. Iyer A, Zurolo E, Spliet WG, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. *Epilepsia* 2010;51:1763–1773.
82. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol* 2011;10:745–758.
83. Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. *Blood* 2009;114:1340–1343.
84. Rojas A, Jiang J, Ganesh T, et al. Cyclooxygenase-2 in epilepsy. *Epilepsia* 2014;55:17–25.
85. Jung KH, Chu K, Lee ST, et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. *Neurobiol Dis* 2006;23:237–246.
86. Holtman L, van Vliet EA, van Schaik R, et al. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. *Epilepsy Res* 2009;84:56–66.
87. Holtman L, van Vliet EA, Edelbroek PM, et al. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. *Epilepsy Res* 2010;91:49–56.
88. Polascheck N, Bankstahl M, Löscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. *Exp Neurol* 2010;224:219–233.
89. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *BMJ* 2006;332:1302–1308.
90. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation* 2007;115:1634–1642.
91. Jiang J, Ganesh T, Du Y, et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. *Proc Natl Acad Sci USA* 2012;109:3149–3154.
92. Jiang J, Quan Y, Ganesh T, et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. *Proc Natl Acad Sci USA* 2013;110:3591–3596.
93. Kwon YS, Pineda E, Auvin S, et al. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. *J Neuroinflammation* 2013;10:30.
94. Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. *Neurology* 2011;76(8 Suppl. 3):S9-14.
95. Gao F, Liu Y, Li X, et al. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. *Pharmacol Biochem Behav* 2012;103:187–196.
96. Cardenas-Rodriguez N, Huerta-Gertrudis B, Rivera-Espinosa L, et al. Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models. *Int J Mol Sci* 2013;14:1455–1476.
97. Rowley S, Patel M. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. *Free Radic Biol Med* 2013;62:121–131.
98. He S, Yan X. From resveratrol to its derivatives: new sources of natural antioxidant. *Curr Med Chem* 2013;20:1005–1017.
99. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. *J Pharmacol Exp Ther* 2012;341:274–284.
100. Shetty AK. Promise of resveratrol for easing status epilepticus and epilepsy. *Pharmacol Ther* 2011;131:269–286.
101. Wu Z, Xu Q, Zhang L, et al. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. *Neurochem Res* 2009;34:1393–1400.
102. Friedman LK, Goldstein B, Rafiuddin A, et al. Lack of resveratrol neuroprotection in developing rats treated with kainic acid. *Neuroscience* 2013;230:39–49.

103. Hybertson BM, Gao B, Bose SK, et al. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. *Mol Aspects Med* 2011;32:234–246
104. Zhang M, An C, Gao Y, et al. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. *Prog Neurobiol* 2013;100:30–47.
105. Winden KD, Karsten SL, Bragin A, et al. A systems level, functional genomics analysis of chronic epilepsy. *PLoS One* 2011;6:e20763.
106. Kraft AD, Lee JM, Johnson DA, et al. Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element. *J Neurochem* 2006; 98:1852–1865.
107. Mazzuferi M, Kumar G, van Eyl J, et al. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. *Ann Neurol* 2013;74:560–568.
108. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. *Trends Pharmacol Sci* 2013;34:340–346.
109. Stangel M, Linker RA. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. *Expert Rev Clin Pharmacol* 2013;6:355–362.
110. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. *Curr Opin Cell Biol* 2005;17:596–603.
111. Sandsmark DK, Pelletier C, Weber JD, et al. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. *Histol Histopathol* 2007;22:895–903.
112. Curatolo P, D'Argenzio L, Cerminara C, et al. Management of epilepsy in tuberous sclerosis complex. *Expert Rev Neurother* 2008;8:457–467.
113. Wong M. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. *Exp Neurol* 2013;244:22–26.
114. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. *J Neurosci* 2009;29:6964–6972.
115. Canpolat M, Per H, Gumus H, et al. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86. *Childs Nerv Syst* 2014;30:227–240.
116. McDaniel SS, Wong M. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. *Neurosci Lett* 2011;497:231–239.
117. Huang X, Zhang H, Yang J, et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. *Neurobiol Dis* 2010;40:193–199.
118. Guo D, Zeng L, Brody DL, et al. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. *PLoS One* 2013;8:e64078.
119. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. *J Neurosci* 2011;31:2337–2347.
120. Kumar G, Mazzuferi M, Otoul C, et al. A randomized, blinded preclinical trial of rapamycin in pilocarpine mouse model of chronic epilepsy. Program No. 560.08. 2011 Neuroscience Meeting Planner. Society for Neuroscience, Washington, DC, 2011.
121. Sliwa A, Plucinska G, Bednarczyk J, et al. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. *Neurosci Lett* 2012;509:105–109.
122. Berger J, Moller DE. The mechanisms of action of PPARs. *Annu Rev Med* 2002;53:409–435.
123. Okada K, Yamashita U, Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. *Brain Res* 2006;1102:175–178.
124. Porta N, Vallée L, Lecointe C, et al. Fenofibrate, a peroxisome proliferator-activated receptor- α agonist, exerts anticonvulsive properties. *Epilepsia* 2009;50:943–948.
125. Sun H, Huang Y, Yu X, et al. Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. *Int J Dev Neurosci* 2008;26:505–515.
126. Hong S, Xin Y, HaiQin W, et al. The PPAR γ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus. *Neurol Sci* 2012;33:559–566.
127. Chuang YC, Lin TK, Huang HY, et al. Peroxisome proliferator-activated receptors γ /mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. *J Neuroinflammation* 2012;9:184.
128. Hong S, Xin Y, HaiQin W, et al. The PPAR γ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus. *Neurochem Int* 2013;63:405–412.
129. Bugge TH, Kombrinck KW, Flick MJ, et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. *Cell* 1996;87:709–719.
130. Qian Z, Gilbert ME, Colicos MA, et al. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. *Nature* 1993;361:453–457.
131. Tsirka SE, Gualandris A, Amaral DG, et al. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue-plasminogen activator. *Nature* 1995;377:340–344.
132. Tsirka SE, Bugge TH, Degen JL, et al. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. *Proc Natl Acad Sci USA* 1997;94:9779–9781.
133. Wu YP, Siao CJ, Lu W, et al. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. *J Cell Biol* 2000;148:1295–1304.
134. Takao M, Benson MD, Murrell JR, et al. Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. *J Neuropathol Exp Neurol* 2000;59:1070–1086.
135. Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. *J Clin Invest* 2002;109:1571–1578.
136. Chateauvieux S, Grigorakaki C, Morceau F, et al. Erythropoietin, erythropoiesis and beyond. *Biochem Pharmacol* 2011;82:1291–1303.
137. Mikati MA, El Hokayem JA, El Sabban ME. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. *Epilepsia* 2007;48:175–181.
138. Bahçekapılı N, Akgün-Dar K, Albeniz I, et al. Erythropoietin pre-treatment suppresses seizures and prevents the increase in inflammatory mediators during pentylenetetrazole induced generalized seizures. *Int J Neurosci* 2014 (in press).
139. Nadam J, Navarro F, Sanchez P, et al. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. *Neurobiol Dis* 2007;25:412–426.
140. Chu K, Jung KH, Lee ST, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. *Epilepsia* 2008;49:1723–1732.
141. Sözmén SÇ, Kurul SH, Yiş U, et al. Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithium-pilocarpine induced status epilepticus. *Brain Dev* 2012;34:189–195.
142. Eid T, Brines ML, Cerami A, et al. Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. *J Neuropathol Exp Neurol* 2004;63:73–83.
143. Marchi N, Lerner-Natoli M. Cerebrovascular remodeling and epilepsy. *Neuroscientist* 2013;19:304–312.

144. Rigau V, Morin M, Rousset MC, et al. Angiogenesis is associated with blood–brain barrier permeability in temporal lobe epilepsy. *Brain* 2007;130:1942–1956.
145. Vezzani A. VEGF and seizures: cross-talk between endothelial and neuronal environments. *Epilepsy Curr* 2005;5:72–74.
146. McCloskey DP, Croll SD, Scharfman HE. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. *J Neurosci* 2005;25:8889–8897.
147. Nicoletti JN, Shah SK, McCloskey DP, et al. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. *Neuroscience* 2008;151:232–241.
148. Cammalleri M, Martini D, Ristori C, et al. Vascular endothelial growth factor up-regulation in the mouse hippocampus and its role in the control of epileptiform activity. *Eur J Neurosci* 2011;33:482–498.
149. Lampson LA. Monoclonal antibodies in neuro-oncology: Getting past the blood–brain barrier. *MAbs* 2011;3:153–160.
150. Croll SD, Goodman JH, Scharfman HE. Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword. *Adv Exp Med Biol* 2004;548:57–68.
151. Morin-Brureau M, Rigau V, Lerner-Natoli M. Why and how to target angiogenesis in focal epilepsies. *Epilepsia* 2012;53(Suppl. 6):64–68.
152. Lee C, Agoston DV. Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury. *Exp Neurol* 2009;220:400–403.
153. Nikitidou L, Kanter-Schlifke I, Dhondt J, et al. VEGF receptor-2 (Flk-1) overexpression in mice counteracts focal epileptic seizures. *PLoS One* 2012;7:e40535.
154. Stancu C, Sima A. Statins: mechanism of action and effects. *J Cell Mol Med* 2001;5:378–387.
155. Adamson P, Greenwood J. How do statins control neuroinflammation? *Inflamm Res* 2003;52:399–403.
156. Lee JK, Won JS, Singh AK, et al. Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death. *Neurosci Lett* 2008;440:260–264.
157. Xie C, Sun J, Qiao W, et al. Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy. *PLoS One* 2011;6:e24966.
158. Lee CY, Jaw T, Tseng HC, et al. Lovastatin modulates glycogen synthase kinase-3 β pathway and inhibits mossy fiber sprouting after pilocarpine-induced status epilepticus. *PLoS One* 2012;7:e38789.
159. van Vliet EA, Holtman L, Aronica E, et al. Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy. *Epilepsia* 2011;52:1319–1330.
160. Osterweil EK, Chuang SC, Chubykin AA, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. *Neuron* 2013;77:243–250.
161. Etninan M, Samii A, Brophy JM. Statin use and risk of epilepsy: a nested case–control study. *Neurology* 2010;75:1496–1500.
162. McNamara JO, Scharfman HE. Temporal lobe epilepsy and the BDNF receptor, TrkB. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. *Jasper's basic mechanisms of the epilepsies*. 4th ed. National Center for Biotechnology Information, Bethesda, MD, 2012, available at: <http://www.ncbi.nlm.nih.gov/books/NBK98186>. Accessed March 16, 2014.
163. Paradiso B, Zucchini S, Su T, et al. Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. *Epilepsia* 2011;52:572–578.
164. Bovolenta R, Zucchini S, Paradiso B, et al. Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. *J Neuroinflammation* 2010;7:81.
165. Liu G, Gu B, He XP, et al. Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. *Neuron* 2013;79:31–38.
166. Weinshenker D, Szot P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. *Pharmacol Ther* 2002;94:213–233.
167. Pitkänen A, Narkilahti S, Bezvenyuk Z, et al. Atipamezole, an α_2 -adrenoceptor antagonist, has disease modifying effects on epileptogenesis in rats. *Epilepsy Res* 2004;61:119–140.
168. Halonen T, Kotti T, Tuunanen J, et al. Alpha2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. *Brain Res* 1995;693:217–224.
169. Wallace MJ, Blair RE, Falenski KW, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. *J Pharmacol Exp Ther* 2003;307:129–137.
170. Chen K, Neu A, Howard AL, et al. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. *J Neurosci* 2007;27:46–58.
171. Echegoyen J, Armstrong C, Morgan RJ, et al. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. *Epilepsy Res* 2009;85:123–127.
172. Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. *Epilepsia* 2013;54:9–12.
173. Löscher W, Puskarjov M, Kaila K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. *Neuropharmacology* 2013;69:62–74.
174. Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. *Ann Neurol* 2008;63:222–235.
175. Mazarati A, Shin D, Sankar R. Bumetanide inhibits rapid kindling in neonatal rats. *Epilepsia* 2009;50:2117–2122.
176. Brandt C, Nodadze M, Heuchert N, et al. Disease-modifying effects of phenobarbital and NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. *J Neuroscience* 2010;30:8602–8612.
177. Töpfer M, Töllner K, Brandt C, et al. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy. *Eur J Neurosci* 2014;39:673–687.
178. Engel J Jr, Pitkänen A, Loeb JA, et al. Epilepsy biomarkers. *Epilepsia* 2013;54(Suppl. 4):61–69.